Article
Professor Anat Lowenstein talks about the impact of Ozurdex in treating diabetic macular edema (DME) in the real world clinical setting. This renowned expert in the DME field, explores what the licensing of Ozurdex in DME means to both patients and retinal specialists when treating this potentially blinding condition.
Redirect to video article
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.